The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

The solution leverages AI to match molecular, demographic, and clinical history data against eligibility criteria from active trials. Credit: MUNGKHOOD STUDIO / Shutterstock.com. Anova Enterprises has ...

MSD’s T-cell engager, MK-1045, has demonstrated its tolerability and efficacy in a Phase Ib/II study in B-cell acute lymphocytic leukaemia (B-ALL). Image credit: HJBC via Shutterstock.com. MSD said ...